AUSVAXSAFETY summary report 2020: 14-16 year infographic

Fourteen to sixteen year schedule point.


AUSVAXSAFETY summary report 2020: 14-16 year infographic

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Publication type:
General public

14,209 parents/carers responded to an SMS about their child’s health a few days after their meningococcal ACWY vaccination. 95% reported no adverse events. 5% reported any adverse event, including 0.3% who reported taking their child to a doctor or emergency department in the days after vaccination. The adverse events they reported were similar to the types of adverse events reported overall. 655 parents/carers reported one or more adverse events. The most commonly reported were tiredness (195 reports), injection site pain (190 reports), headache (178 reports),  injection site swelling or redness (141 reports) and fever (103 reports). These symptoms are known to occur after vaccination. They are generally mild and short-lived. Aboriginal and Torres Strait Islander children who received this vaccine had the same rates and types of adverse events as other children. The vaccine given at 14–16 years in 2020 is Nimenrix (protects against meningococcal disease types A, C, W and Y).

Part of a collection:

Help us improve

If you would like a response please use the enquiries form instead.